Skip to main content

Table 3 Clinical and pathological data on malignant tumour samples where available

From: Identification of suitable endogenous control genes for microRNA gene expression analysis in human breast cancer

Patient
Number
Patient
Age
Menopausal
status
Size
(mm)
T N M Grade ER PR HER2/
neu
Subtype Metastatic
grouping
1 41 Pre 25 2 0 0   P    Luminal A/B MF
2 50 Pre 35 2 1 0 1 P P N Luminal A MF
3 38 Post 35 2 1 0 1 P P N Luminal A MF
4 43 Pre 10 1 0 0 1 P P N Luminal A MF
5 49 Post 20 1 1 0 2 P N N Luminal A MF
6 78 Post 20 1 1 0 1 P P N Luminal A MF
7 51 Post 18 1 0 0   N   N LuminalA/Basal MF
8 75 Post 36 4 1 0 2 P    Luminal A/B MF
9 59 Post 50 2 1 0 3 P P N Luminal A BM
10 53 Post 85 3 1 0 3 N N N Basal MF
11 43 Pre 50 2 1 0 3 P N N Luminal A MF
12 69 Post 35 4 2 0 3 P P N Luminal A VBM
13 66 Post 12 1 0 0 3 P N N Luminal A MF
14 58 Post 20 4 1 0 2 P P N Luminal A MF
15 58 Post 15 1 1 0 2 P P N Luminal A VBM
16 70 Post 20 1 0 0 2 P P N Luminal A MF
17 52 Post 25 4 1 0 3 P P P Luminal B VBM
18 78 Post   1 0 0   P P N Luminal A BM
19 61 Post 33 2 1 0 1 P P P Luminal B BM
20 48 Pre 30 2 1 0 3 P P N Luminal A VBM
21 50 Pre 30 2 1 0 3 N N   Basal/HER-2 VBM
22 51 Post 20 1   0 1 P    Luminal A/B VBM
23 69 Post 40 2 1 0 2 P N N Luminal A BM
24 58 Post 21 4   0 3 N N P HER-2 BM
25 61 Post 35 2 1 0 3 P P N Luminal A BM
26 64 Post 15 1 1 0 2 P N P Luminal B BM
  1. T, N and M refer to the primary tumor size, nodal status and distant metastases status according to the TNM breast cancer classification system. ER: = oestrogen receptor status; PR: = progesterone receptor status and HER2/neu = v-erb-b2 erythroblastic leukaemia viral oncogene status. Where data was not available for ER, PR and HER-2, possible subtype based on available hormone receptor status is given. Metastatic groupings refer to patient status five years after presentation; patients were either metastases-free (MF), had developed bone metastases (BM) or had developed visceral and bone metastases (VBM).
\